CX 2019: Cook leads the way to data transparency with release of long-term ZILVER PTX patient-level data

969


There were calls for greater transparency and sharing of the available randomised controlled trial data of paclitaxel-coated devices at the CX 2019 Highlight Session, Paclitaxel: The Last Word. The session also emphasised the need for a meta-analysis of individual patient-level data going forward.

Cook Medical has just announced the release of de-identifiable patient-level data for the ZILVER PTX randomised controlled trial.

Vascular News spoke to Michael Dake (Tucson, USA), Gary Ansel (Columbus, USA) and Aaron Lottes (West Lafayette, USA) about why this is an important step, and the highlights of the Zilver PTX five-year safety and mortality data.

For more information about Zilver PTX, and to request the patient-level data, visit cookmedical.com 

This video is sponsored by Cook Medical.

(Visited 361 times, 1 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here